BioAscent offers customers straightforward and cost-effective access to the big-pharma calibre compound management capabilities and expertise at our €20 million facility. We give customers the peace-of-mind that their compounds are aggregated and stored securely, their inventory is up-to-date and trackable, and compounds can be accessed and delivered quickly and easily – something that is especially critical for innovative biotechs working with a network of CROs.
We manage libraries of all sizes, ranging from tens to hundreds-of-thousands of compounds. But our customers all have this in common – they choose BioAscent to cost-effectively and securely manage their compounds, connect their CRO network, and accelerate their design-make-test cycles.
Our customers benefit from rapid compound sourcing and aggregation, secure storage, up-to-date visibility of all samples and orders with a full audit trail, and rapid delivery of solids or liquids in any format, up to and including screen-ready Assay Ready Plates (ARPs).
Secure, flexible, trackable compound aggregation, storage and management
Visibility of inventory at all times via Compound Connect
Flexible and auditable cherry picking, reformatting and shipping
Any plate format and layout, including nanolitre acoustic dispensing to assay ready plates, near assay ready plates, dose response curve (DRC) plates, and compound pooling
Rapid delivery to in-house labs or CRO partners across the globe
Rapid selection and sourcing of custom libraries: established partnerships with compound suppliers/aggregators
We work with customers and libraries both small and large – from start-up biotech to big pharma
Cost-effective, transparent activity-based pricing
Licence to manage and test controlled/scheduled substances
Member of the Institute of Export & International Trade
“ODD has been working with BioAscent for over two years, since we transferred our entire compound management to them. The logistical services are reasonably priced and reduce the burden on our chemists for weighing and dispatching allowing greater productivity. BioAscent can accommodate varying storage requirements for our compounds that reflect differing stabilities and are able to perform analysis on the samples when needed. The shipping turnaround from BioAscent is always rapid and they can accommodate differing shipping formats and often, last-minute changes in our requirements.” – Oxford Drug Design.
We manage libraries of all sizes for over 70 customers from across the globe, ranging from big pharma to virtual biotechs and charity and academic consortia in both North America and Europe, and we currently hold and manage over 1.5 million compounds for them in both liquid and solid formats. Via the European Lead Factory we also provide compound management for collections from AstraZeneca, Bayer, Grunenthal, Janssen, Merck KgaA, Sanofi, Servier and UCB.
Our expertise in cherry picking, reformatting, shipping and data management has allowed us to deliver over 100,000 screening plates globally to our customers and their partner testing laboratories since 2013.
“VAST Bioscience was looking for a compound management provider that is competitively priced, and is fast and flexible in order to service both our screening collaborations of VAST libraries, and our internal drug discovery programs. We have been very pleased with the professionalism that BioAscent has brought to the table, in particular the rapid response and turnaround time for delivering plating orders and shipment, combined with the flexibility and attention to detail. BioAscent has been reliable, timely and accurate, and it was very pleasing to see the positive impact on our internal and external projects.” – VAST Bioscience
Our compound management services allow our customers to both save costs and accelerate their drug discovery. Operating since 2005, our €20 million facility stores and manages customer libraries ranging in size from tens to hundreds-of-thousands of compounds in both liquid and solid formats. We support all stages of the drug discovery process from screening and hit identification through to lead optimisation and candidate selection, with on-site in vitro biosciences and medicinal chemistry available if required.
BioAscent can support some or all of your key compound management activities including aggregation, storage, weighing, dissolution, plating (including acoustic dispensing and Assay Ready Plates), LC-MS analysis and distribution. We provide both standalone activities on a fee-for service basis, as well as fully integrated compound management services. However you work with us, a dedicated account manager works with you and your R&D partners, and our transparent activity pricing makes it easy to calculate cost savings.
Developed by BioAscent, Compound Connect is our web-based interface providing customers with secure access to a customised, online inventory and ordering system for their compound library. The fully auditable order fulfilment system interfaces with the BioAscent Titian Mosaic compound management system and is also compatible with existing customer informatics systems.
Compound Connect is easy to use and secure, and allows customers to:
Make deposits and upload details of compounds to be added to their inventory
View and search an up-to-date compound inventory Create orders, specifying which compounds are to be processed for weighing as solids, for dissolution in 100% DMSO or to be plated.
Manage dispatches to CROs and partners across the globe, and view dispatch history.
Download more information about Compound Connect here.
“Our partnership with BioAscent combines our long-standing expertise in high content cell based phenotypic screening with BioAscent’s expertise in compound management and quality control processes for compound storage, identification and resupply. Our discussions with BioAscent have been very dynamic and interactive which has helped ensure we developed the compound management solution which best meets our needs. The ongoing relationship with BioAscent and their fast response times are directly supporting our broader goals to establish a world leading cell based screening capability which spans across multiple disease areas” – Neil Carragher, Professor of Drug Discovery, University of Edinburgh.
Operating since 2005, our €20 million facility stores and manages customer libraries ranging in size from tens to hundreds-of-thousands of compounds in both liquid and solid formats. We continually invest in new cutting-edge equipment, software and expertise to provide our customers with cost-effective, big-pharma calibre compound management services, and the cycle-time savings and security that these services deliver.
The BioAscent compound management team is led by Dr Sylviane Boucharens. A drug discovery and compound management expert with over 20 years of pharmaceutical industry experience, Sylviane led the global compound repository team and the in vitro screening team at the Merck Sharpe & Dohme / Schering Plough / Organon site in Newhouse, Scotland at which BioAscent is now based.
Sylviane is supported by a team of experts in compound management, data management, software development, logistics, and computational chemistry working in state-of-the-art facilities originally commissioned to manage Merck Sharpe & Dohme’s global collection.
Maximising Efficient Compound Management by Jennifer Ellis, Biocompare. S. Boucharens, M. Piper. View article.
Comprehensive Medicinal Chemistry III, Chapter 1.18, 505-519; Eds. S. Chackalamannil, D. Rotella, S. Ward; Oxford: Elsevier; 2017. European Lead Factory; F. Giordanetto, P. Jones, A. Nelson, J. Benningshof, G. Muller, A. Pannifer, S. van Boeckel, D. Tzalis. View paper.
Compound Interest. European Biopharmaceutical Review October 2014: 62-65. S. MacKenzie, S. Boucharens.
Outsourcing Sample Management. Management of Chemical and Biological samples for screening application. Edited by Wigglesworth M. and Wood T. WILEY VCH Chapter 18 (ISBN: 978-3-527-32822-2). S. Boucharens, A. Warner.
Outsourcing Compound Inventory: Trend or real Benefits. Pharmaceutical Outsourcing November/December 2010. S.Boucharens. View paper.
Let's talk about how we can maximise your drug discovery success.